In particular, c-MYC was found to be overexpressed in AML, both in the presence and in the absence of a chromosomal translocation, as well as in pediatric subtypes and those forms related to cytotoxic therapy [43–46], and its role in AML development has been proved in vivo [47, 48]. Here, MYC is linked to acute myeloid leukemia.